NCT00885638

Brief Summary

The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_4 healthy

Timeline
Completed

Started Aug 2009

Longer than P75 for phase_4 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 21, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 22, 2009

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2009

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2011

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
5 months until next milestone

Results Posted

Study results publicly available

January 15, 2013

Completed
Last Updated

January 30, 2014

Status Verified

December 1, 2013

Enrollment Period

1.7 years

First QC Date

April 21, 2009

Results QC Date

September 21, 2012

Last Update Submit

December 25, 2013

Conditions

Keywords

GLP-1Insulin secretionMacronutrients

Outcome Measures

Primary Outcomes (1)

  • Glucagon-like Peptide-1 Secretion After Meal Ingestion

    Plasma GLP-1 levels will be measured during 300 min after meal ingestion for estimation of GLP-1 secretion

    300 min

Secondary Outcomes (1)

  • Insulin Secretion After Ingestion of Meal

    300 min

Study Arms (2)

Placebo

PLACEBO COMPARATOR

A placebo tablet is given before ingestion of macronutrients

Drug: placebo

Sitagliptin

ACTIVE COMPARATOR

Sitagliptin is given before ingestion of macronutrients

Drug: Sitagliptin

Interventions

100 mg sitagliptin before ingestion of macronutrient

Also known as: Januvia
Sitagliptin

A placebo tablet is given before ingestion of macronutrients

Placebo

Eligibility Criteria

Age20 Years - 30 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men
  • Age 20-30 years
  • BMI 20-30 kg/m2

You may not qualify if:

  • Any disease
  • Any medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Clinical Sciences Lund, Lund University

Lund, 221 84, Sweden

Location

Related Publications (2)

  • Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahren B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E779-84. doi: 10.1152/ajpendo.90233.2008. Epub 2008 Jul 8.

    PMID: 18612044BACKGROUND
  • Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A, Ahren B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes Metab. 2013 Jun;15(6):531-7. doi: 10.1111/dom.12062. Epub 2013 Feb 7.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Sitagliptin Phosphate

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyrazines

Results Point of Contact

Title
Professor Bo Ahrén
Organization
Lund University

Study Officials

  • Bo Ahrén, MD, PhD

    Lund University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 21, 2009

First Posted

April 22, 2009

Study Start

August 1, 2009

Primary Completion

May 1, 2011

Study Completion

September 1, 2012

Last Updated

January 30, 2014

Results First Posted

January 15, 2013

Record last verified: 2013-12

Locations